Management Team
Seungil Ro - President and CSO
Seungil Ro, Ph.D. founded RosVivo Therapeutics in
2021 and is its President and CSO. In 2022, he secured
funds for preclinical studies of therapeutic microRNAs
to treat diabetes.
Dr. Ro holds 7 US/International Patents for the treatment of diabetes, obesity, fatty liver disease, and gastrointestinal dysmotility.
He is also a Professor in the Department of Physiology & Cell Biology at the University of Nevada School of Medicine, Reno, Nevada.
Dr. Ro has published 70 articles in multiple high-impact journals including Nature Genetics, Cell Research, Gut, and Gastroenterology, on topics relating to genetic and epigenetic regulation in diabetes, gastrointestinal motility disorders, and cancers.
Dr. Ro holds 7 US/International Patents for the treatment of diabetes, obesity, fatty liver disease, and gastrointestinal dysmotility.
He is also a Professor in the Department of Physiology & Cell Biology at the University of Nevada School of Medicine, Reno, Nevada.
Dr. Ro has published 70 articles in multiple high-impact journals including Nature Genetics, Cell Research, Gut, and Gastroenterology, on topics relating to genetic and epigenetic regulation in diabetes, gastrointestinal motility disorders, and cancers.
David Craig, MBA - CEO
David Craig is a pharmaceutical executive with more than 30 years of experience leading and scaling organizations to commercial success. Mr. Craig has been a member of, and led, teams responsible for the commercialization of blockbuster #1-in-market, or first-in-class, novel medicines including EPOGEN (erythropoietin alfa), NEUPOGEN (filgrastim), HEPSERA (adefovir dipivoxil) and ANDEXXA (andexanet afla). He has held leadership roles at Amgen, Sequus, Gilead Sciences, AcelRx, Portola, and the UNR Licensing Office. Mr. Craig earned a BS in Pharmacy from South Dakota State University and an MBA from the Pepperdine Graziadio Business School.
Sandra M. Poudrier - COO
Sandra has 25 years of experience in biotech in all aspects of product lifecycles from basic research to scale-up, cGMP manufacturing, product validation, and post-marketing product support, She has a patent for a diagnostic assay for pancreatitis. Sandra was also an original member of Dr. Ro's research team which discovered the regulatory role miRNAs have on gut motility, diabetes, and obesity,
Prior to working with Dr. Ro, Sandra was the Director of Quality for two divisions of a multi-national company and was responsible for the development, oversight, and execution of their international regulatory and quality systems whose served multinational customers such as ExxonMobil, Chevron Corporations and KOGAS.
Prior to working with Dr. Ro, Sandra was the Director of Quality for two divisions of a multi-national company and was responsible for the development, oversight, and execution of their international regulatory and quality systems whose served multinational customers such as ExxonMobil, Chevron Corporations and KOGAS.